Stock Analysis on Net
Stock Analysis on Net

Analysis of Short-term (Operating) Activity Ratios
Quarterly Data

Microsoft Excel

Short-term Activity Ratios (Summary)

Eli Lilly & Co., short-term (operating) activity ratios (quarterly data)

Microsoft Excel
Jun 30, 2026 Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Turnover Ratios
Inventory turnover 0.79 0.85 0.80 0.83 0.84 0.96 1.11 1.05 1.16 1.17 1.23 1.40 1.37 1.36 1.54 1.86 1.79 1.93
Receivables turnover 3.97 3.92 3.67 3.69 3.76 4.07 4.09 3.97 3.53 4.56 3.75 3.93 3.93 3.68 4.14 4.35 4.57 4.64
Payables turnover 2.16 2.47 2.05 2.37 2.27 2.61 2.61 2.70 2.56 2.88 2.73 2.81 2.65 3.07 3.43 4.24 4.21 5.24
Working capital turnover 4.71 3.97 3.19 2.71 4.92 4.38 10.32 6.06 12.62 5.45 31.79 12.21 5.77 31.84 14.71 19.45 8.19
Average No. Days
Average inventory processing period 463 428 454 441 435 379 329 349 316 312 298 261 267 268 237 196 204 189
Add: Average receivable collection period 92 93 99 99 97 90 89 92 103 80 97 93 93 99 88 84 80 79
Operating cycle 555 521 553 540 532 469 418 441 419 392 395 354 360 367 325 280 284 268
Less: Average payables payment period 169 148 178 154 161 140 140 135 142 127 134 130 138 119 106 86 87 70
Cash conversion cycle 386 373 375 386 371 329 278 306 277 265 261 224 222 248 219 194 197 198

Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).


The analyzed period reveals a systemic deceleration in short-term operating efficiency, characterized by a significant lengthening of the cash conversion cycle and a marked slowdown in inventory movement. While receivables management remains relatively stable, there is a clear trend toward extended payment terms for suppliers and a substantial increase in the time required to process inventory.

Inventory Management
A persistent downward trend is observed in inventory turnover, which declined from 1.93 in March 2022 to 0.79 by June 2026. Correspondingly, the average inventory processing period expanded significantly, rising from 189 days to 463 days. This indicates a substantial increase in the volume of capital tied up in unsold stock and a decrease in the velocity of inventory throughput.
Receivables Management
Receivables turnover demonstrates relative stability compared to other activity ratios, fluctuating between a high of 4.64 and a low of 3.53. The average receivable collection period remained largely consistent, moving from 79 days in March 2022 to 92 days in June 2026, suggesting that the company has maintained a steady pace of collections from its customers despite other operational shifts.
Payables Management
A notable decline in payables turnover is evident, dropping from 5.24 to 2.16 over the period. This is reflected in the average payables payment period, which more than doubled from 70 days to 169 days. Such a trend suggests a strategic shift toward delaying payments to suppliers to preserve liquidity or a change in credit terms provided by vendors.
Operating and Cash Conversion Cycles
The operating cycle has experienced a sharp increase, growing from 268 days to 555 days, driven primarily by the deterioration in inventory turnover. Although the extension of the payables payment period partially offset this increase, the cash conversion cycle still expanded significantly from 198 days to 386 days. This indicates a widening gap between the cash outlay for raw materials and the cash recovery from sales.
Working Capital Efficiency
Working capital turnover exhibits high volatility throughout the period, with extreme peaks reaching 31.84 in December 2022 and September 2023. However, the long-term trend shows a regression toward lower values, ending at 4.71 in June 2026, which correlates with the overall increase in working capital requirements and slower asset turnover.

AI Ask an analyst for more


Turnover Ratios


Average No. Days



Inventory Turnover

Eli Lilly & Co., inventory turnover calculation (quarterly data)

Microsoft Excel
Jun 30, 2026 Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in millions)
Cost of sales 3,268 3,577 3,372 3,008 2,448 2,224 2,404 2,171 2,170 1,674 1,788 1,860 1,807 1,627 1,548 1,579 1,431 2,072
Inventories 16,793 14,529 13,744 12,180 11,014 9,311 7,589 7,460 6,482 6,102 5,773 4,901 4,799 4,545 4,310 3,831 3,899 3,893
Short-term Activity Ratio
Inventory turnover1 0.79 0.85 0.80 0.83 0.84 0.96 1.11 1.05 1.16 1.17 1.23 1.40 1.37 1.36 1.54 1.86 1.79 1.93
Benchmarks
Inventory Turnover, Competitors2
AbbVie Inc. 3.58 3.65 3.68 3.65 3.42 3.71 4.04 4.09 4.86 4.83 4.98 4.74 4.30 4.53 4.87 5.54 4.99 4.96
Amgen Inc. 1.87 1.91 1.93 1.92 1.88 1.88 1.84 1.75 1.42 1.14 0.89 1.41 1.38 1.31 1.30 1.34 1.40 1.48
Bristol-Myers Squibb Co. 5.36 5.20 5.18 5.31 5.18 5.28 5.46 3.57 3.72 3.70 4.02 4.33 4.39 3.93 4.33 4.77 4.59 4.55
Danaher Corp. 3.20 3.90 4.04 3.67 3.60 3.79 4.15 3.60 3.59 3.73 3.80 3.53 3.58 3.50 4.03 3.80 3.71 3.87
Gilead Sciences Inc. 3.18 3.21 3.51 3.47 3.40 3.55 3.66 3.62 3.33 3.59 3.64 3.49 3.45 3.57 3.75 4.71 4.50 4.50
Johnson & Johnson 2.08 2.13 2.13 2.08 2.17 2.24 2.21 2.15 2.20 2.32 2.37 2.46 2.23 2.36 2.49 2.68 2.69 2.77
Merck & Co. Inc. 2.90 2.65 2.46 2.27 2.25 2.43 2.49 2.45 2.39 2.42 2.54 2.63 2.66 2.72 2.95 3.10 3.06 2.74
Pfizer Inc. 1.72 1.57 1.51 1.46 1.52 1.60 1.65 1.66 2.05 2.15 2.45 2.65 2.31 3.07 3.82 3.62 3.66 3.67
Regeneron Pharmaceuticals Inc. 0.76 0.74 0.66 0.64 0.64 0.63 0.64 0.64 0.65 0.66 0.70 0.72 0.69 0.67 0.65 0.83 0.96 1.27
Thermo Fisher Scientific Inc. 4.87 4.87 4.85 4.47 4.57 4.82 5.06 4.62 4.83 4.93 5.06 4.83 4.64 4.62 4.60 4.29 4.03 3.87
Vertex Pharmaceuticals Inc. 1.00 0.95 0.98 0.99 1.06 1.14 1.27 1.37 1.53 1.65 1.71 1.71 1.90 2.06 2.35 2.69 2.70 2.83

Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q2 2026 Calculation
Inventory turnover = (Cost of salesQ2 2026 + Cost of salesQ1 2026 + Cost of salesQ4 2025 + Cost of salesQ3 2025) ÷ Inventories
= (3,268 + 3,577 + 3,372 + 3,008) ÷ 16,793 = 0.79

2 Click competitor name to see calculations.


An analysis of short-term operating activity reveals a significant and sustained decline in inventory efficiency from March 2022 through June 2026. While both cost of sales and total inventory levels increased over this period, the rate of inventory accumulation substantially outpaced the growth in sales costs, resulting in a consistent downward trend in the inventory turnover ratio.

Cost of Sales Trends
Cost of sales demonstrated a general upward trajectory, rising from 2,072 million USD in March 2022 to 3,268 million USD by June 2026. A period of accelerated growth is evident starting in the first quarter of 2024, with the highest quarterly expenditure recorded in March 2026 at 3,577 million USD.
Inventory Accumulation
Inventory levels experienced an aggressive expansion, increasing from 3,893 million USD in March 2022 to 16,793 million USD by June 2026. The pace of growth intensified markedly starting in March 2024, as balances rose from 6,102 million USD to over 16 billion USD by the end of the observed period, representing more than a fourfold increase in total holdings.
Inventory Turnover Ratio Analysis
The inventory turnover ratio declined steadily from 1.93 in March 2022 to 0.79 in June 2026. The ratio fell below the 1.0 threshold in March 2025 and remained below this level through June 2026. This pattern indicates a widening gap between the acquisition or production of inventory and the realization of those goods through sales, suggesting a strategic build-up of stock or a decrease in the velocity of inventory movement relative to the scale of operations.

AI Ask an analyst for more



Receivables Turnover

Eli Lilly & Co., receivables turnover calculation (quarterly data)

Microsoft Excel
Jun 30, 2026 Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in millions)
Revenue 22,974 19,799 19,292 17,601 15,558 12,729 13,533 11,439 11,303 8,768 9,353 9,499 8,312 6,960 7,302 6,942 6,488 7,810
Accounts receivable 20,083 18,429 17,760 16,107 14,170 12,037 11,006 10,295 11,028 7,886 9,091 8,167 7,516 7,526 6,896 6,715 6,365 6,323
Short-term Activity Ratio
Receivables turnover1 3.97 3.92 3.67 3.69 3.76 4.07 4.09 3.97 3.53 4.56 3.75 3.93 3.93 3.68 4.14 4.35 4.57 4.64
Benchmarks
Receivables Turnover, Competitors2
AbbVie Inc. 4.66 5.03 4.86 4.67 4.62 4.60 5.16 4.84 4.69 4.55 4.87 4.83 4.88 4.95 5.16 5.38 5.10 5.29
Amgen Inc. 3.55 3.88 3.67 4.06 3.85 4.03 4.72 4.26 4.26 4.16 3.70 4.17 4.34 4.34 4.46 4.60 4.62 4.81
Danaher Corp. 6.33 6.49 6.28 6.46 6.74 6.79 6.75 6.77 7.15 7.02 6.09 6.15 6.64 6.89 6.40 7.09 6.81 6.87
Gilead Sciences Inc. 5.90 6.17 5.89 5.60 6.01 6.51 6.47 6.14 5.92 5.84 5.78 5.68 6.43 6.43 5.65 6.16 6.60 7.18
Johnson & Johnson 5.14 5.44 5.48 5.23 5.08 5.58 5.98 5.42 5.48 5.73 5.73 5.91 5.36 5.65 5.88 6.04 5.92 6.08
Merck & Co. Inc. 5.30 5.39 5.52 5.30 5.37 5.92 6.24 5.55 5.37 5.40 5.81 5.71 5.29 5.56 6.27 6.22 5.93 5.49
Pfizer Inc. 5.10 5.03 5.27 4.40 5.29 5.27 5.55 4.18 4.93 5.09 5.33 6.25 7.66 7.57 9.16 6.21 6.68 6.99
Regeneron Pharmaceuticals Inc. 2.37 2.60 2.50 2.51 2.53 2.53 2.29 2.27 2.36 2.51 2.31 2.35 2.47 2.42 2.28 2.47 2.76 3.41
Thermo Fisher Scientific Inc. 4.90 4.91 5.01 4.91 5.03 5.07 5.23 5.13 5.33 5.36 5.21 5.19 5.43 5.53 5.53 5.76 5.53 5.21
Vertex Pharmaceuticals Inc. 5.90 6.12 5.85 6.02 6.03 6.15 6.85 6.07 6.24 5.68 6.31 6.27 6.11 5.95 6.19 6.28 6.26 6.15

Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q2 2026 Calculation
Receivables turnover = (RevenueQ2 2026 + RevenueQ1 2026 + RevenueQ4 2025 + RevenueQ3 2025) ÷ Accounts receivable
= (22,974 + 19,799 + 19,292 + 17,601) ÷ 20,083 = 3.97

2 Click competitor name to see calculations.


Analysis of short-term operating activity indicates a period of aggressive expansion in both revenue generation and the associated credit balance. Revenue increased from 7,810 million US dollars in March 2022 to 22,974 million US dollars by June 2026. Simultaneously, accounts receivable grew from 6,323 million US dollars to 20,083 million US dollars over the same period, reflecting a scaling of operations.

Receivables Turnover Volatility
The receivables turnover ratio exhibited a general downward trend during the first year of the analyzed period, declining from 4.64 in March 2022 to 3.68 by March 2023. While a temporary recovery to 4.56 occurred in March 2024, the ratio subsequently stabilized within a range between 3.53 and 4.09. This movement suggests a moderate decrease in the efficiency of receivable collections or a strategic shift toward more extended credit terms to support rapid sales growth.
Growth Correlation
A strong positive correlation is observed between the growth in revenue and the increase in accounts receivable. As revenue scaled, particularly after December 2023, the balance of outstanding receivables rose proportionally. The observation that the turnover ratio remained relatively stable, fluctuating primarily between 3.6 and 4.1 during the latter half of the period, indicates that the company maintained a consistent collection cycle despite the significant increase in the volume of sales.
Recent Performance Trends
In the final quarters ending March and June 2026, a slight upward trend in the turnover ratio is noted, moving from 3.92 to 3.97. This indicates a marginal improvement in the speed of converting receivables into cash, occurring even as revenue reached its peak of 22,974 million US dollars.

AI Ask an analyst for more



Payables Turnover

Eli Lilly & Co., payables turnover calculation (quarterly data)

Microsoft Excel
Jun 30, 2026 Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in millions)
Cost of sales 3,268 3,577 3,372 3,008 2,448 2,224 2,404 2,171 2,170 1,674 1,788 1,860 1,807 1,627 1,548 1,579 1,431 2,072
Accounts payable 6,112 5,029 5,379 4,262 4,076 3,442 3,229 2,887 2,925 2,474 2,599 2,435 2,474 2,016 1,931 1,683 1,659 1,433
Short-term Activity Ratio
Payables turnover1 2.16 2.47 2.05 2.37 2.27 2.61 2.61 2.70 2.56 2.88 2.73 2.81 2.65 3.07 3.43 4.24 4.21 5.24
Benchmarks
Payables Turnover, Competitors2
Amgen Inc. 4.05 4.02 5.09 4.29 4.12 5.25 6.74 5.99 5.01 6.10 5.32 5.22 5.67 4.97 4.08 5.30 5.09 4.65
Bristol-Myers Squibb Co. 3.53 3.38 3.90 3.42 2.61 3.52 3.88 3.43 3.05 3.12 3.28 3.75 3.38 3.20 3.33 3.82 3.41 3.25
Danaher Corp. 5.72 5.68 5.45 5.78 5.62 5.57 5.52 6.04 5.84 5.88 5.58 5.63 5.82 5.68 5.45 5.61 5.00 5.04
Gilead Sciences Inc. 9.22 9.52 8.72 7.66 10.65 8.47 7.50 7.49 12.57 10.69 11.81 9.90 9.06 8.99 6.25 11.22 11.89 11.43
Johnson & Johnson 3.41 2.96 2.52 3.06 3.07 2.97 2.66 3.03 3.03 3.23 2.76 3.29 2.75 3.05 2.66 3.08 3.15 3.26
Merck & Co. Inc. 4.70 4.44 3.72 3.53 3.82 3.98 3.72 4.26 4.39 4.48 4.11 4.59 4.58 4.34 4.08 5.16 4.86 4.25
Pfizer Inc. 3.73 3.72 3.07 3.32 3.44 3.30 3.17 3.67 4.60 4.19 3.72 5.07 3.92 4.78 5.04 5.49 6.17 6.66
Regeneron Pharmaceuticals Inc. 2.03 2.24 2.24 2.30 2.83 2.84 2.50 3.87 3.32 2.67 2.99 3.43 3.14 2.69 2.65 3.74 4.00 5.39
Thermo Fisher Scientific Inc. 8.39 8.00 7.27 8.23 8.53 8.25 8.18 9.63 9.85 9.91 8.97 10.41 10.82 9.35 7.67 9.93 8.84 7.96
Vertex Pharmaceuticals Inc. 4.10 3.44 3.58 3.83 3.59 3.49 3.71 3.73 4.27 3.81 3.46 3.13 3.16 3.41 3.55 8.23 5.01 5.52

Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q2 2026 Calculation
Payables turnover = (Cost of salesQ2 2026 + Cost of salesQ1 2026 + Cost of salesQ4 2025 + Cost of salesQ3 2025) ÷ Accounts payable
= (3,268 + 3,577 + 3,372 + 3,008) ÷ 6,112 = 2.16

2 Click competitor name to see calculations.


A comprehensive analysis of the operating activity ratios reveals a sustained downward trend in the payables turnover ratio from March 2022 through June 2026. This decline indicates a slowing rate of supplier payment and a systemic increase in the period during which the company holds onto its cash before settling obligations with vendors.

Payables Turnover Trajectory
The payables turnover ratio experienced a significant contraction, falling from a high of 5.24 in March 2022 to 2.16 by June 2026. The most rapid decline occurred between March 2022 and June 2023, where the ratio dropped from 5.24 to 2.65. Following this initial period of volatility, the ratio entered a phase of relative stabilization, fluctuating within a tighter range between 2.05 and 2.88 through the remainder of the analyzed period.
Analysis of Primary Drivers
The deterioration of the turnover ratio is primarily driven by a disproportionate growth in accounts payable relative to the cost of sales. While the cost of sales increased from 2,072 million in March 2022 to 3,268 million in June 2026, accounts payable grew at a far more aggressive rate, rising from 1,433 million to 6,112 million over the same period. This indicates that the growth in liabilities to suppliers significantly outpaced the growth in the actual cost of goods sold.
Working Capital Implications
The expansion of accounts payable suggests a strategic shift in working capital management. By extending the payment cycle, the organization has effectively increased its cash conversion efficiency by utilizing supplier credit as a source of short-term financing. The lowest turnover ratio of 2.05 was recorded in December 2025, coinciding with a peak in accounts payable of 5,379 million, highlighting a period of maximum leverage of supplier terms.
Operational Correlation
Despite fluctuations in the cost of sales—which saw a notable peak of 3,577 million in March 2026—the accounts payable balance maintained a consistent upward trajectory. This divergence suggests that the increase in payment terms is not merely a reaction to seasonal spikes in costs, but rather a long-term structural change in procurement and payment policies.

AI Ask an analyst for more



Working Capital Turnover

Eli Lilly & Co., working capital turnover calculation (quarterly data)

Microsoft Excel
Jun 30, 2026 Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in millions)
Current assets 64,672 54,835 55,629 62,071 49,854 41,261 32,740 31,415 30,204 25,189 25,727 23,007 21,332 20,811 18,035 17,640 17,115 16,965
Less: Current liabilities 47,741 36,634 35,228 40,141 39,020 30,068 28,377 24,674 27,121 18,598 27,293 21,998 18,915 16,010 17,138 15,653 15,621 13,386
Working capital 16,931 18,201 20,401 21,930 10,834 11,193 4,363 6,741 3,083 6,591 (1,566) 1,009 2,417 4,801 896 1,987 1,495 3,579
 
Revenue 22,974 19,799 19,292 17,601 15,558 12,729 13,533 11,439 11,303 8,768 9,353 9,499 8,312 6,960 7,302 6,942 6,488 7,810
Short-term Activity Ratio
Working capital turnover1 4.71 3.97 3.19 2.71 4.92 4.38 10.32 6.06 12.62 5.45 31.79 12.21 5.77 31.84 14.71 19.45 8.19
Benchmarks
Working Capital Turnover, Competitors2
AbbVie Inc.
Amgen Inc. 3.83 5.44 9.85 5.66 5.35 8.36 5.40 4.83 5.19 3.39 2.25 0.81 0.84 0.82 3.82 2.52 3.67 4.34
Bristol-Myers Squibb Co. 4.81 5.84 7.83 6.20 8.09 6.87 7.79 8.49 12.50 15.56 4.60 10.47 5.53 5.55 8.30 5.75 4.92 6.24
Danaher Corp. 4.76 3.83 4.13 7.39 5.71 8.27 8.85 8.73 8.10 3.60 4.22 2.18 3.08 3.81 4.20 5.00 5.43 5.91
Gilead Sciences Inc. 10.20 3.19 4.43 5.12 8.14 6.27 3.99 9.22 17.98 26.58 5.61 6.74 84.15 9.14 8.42 8.56 6.87 6.68
Johnson & Johnson 20.07 66.14 62.88 24.63 284.99 6.10 15.94 58.86 22.29 10.35 11.81 9.37 14.06 23.02 4.88 5.02 5.57
Merck & Co. Inc. 7.44 8.15 4.28 3.39 5.77 6.19 6.19 5.86 5.14 9.68 9.29 6.69 8.86 5.63 5.16 5.58 6.39 6.09
Pfizer Inc. 7.31 7.47 10.58 6.08 10.68 6.64 8.64 5,036.00 29.17 1.62 2.03 6.89 11.00 3.83 5.05 6.10
Regeneron Pharmaceuticals Inc. 1.20 1.14 1.05 1.05 1.08 1.01 0.97 0.88 0.87 0.86 0.82 0.87 0.92 0.90 0.96 1.09 1.14 1.46
Thermo Fisher Scientific Inc. 5.59 5.87 3.30 5.90 3.64 4.20 4.87 4.61 3.96 4.38 4.05 4.86 7.40 10.13 5.46 5.40 6.03 6.13
Vertex Pharmaceuticals Inc. 1.46 1.56 1.64 1.92 1.82 1.78 1.83 1.82 1.92 1.07 0.93 0.87 0.90 0.93 0.85 0.90 0.93 0.97

Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q2 2026 Calculation
Working capital turnover = (RevenueQ2 2026 + RevenueQ1 2026 + RevenueQ4 2025 + RevenueQ3 2025) ÷ Working capital
= (22,974 + 19,799 + 19,292 + 17,601) ÷ 16,931 = 4.71

2 Click competitor name to see calculations.


The financial data exhibits a period of significant expansion in both top-line revenue and the capital required to support operations. While revenue demonstrates a consistent upward trajectory, working capital has experienced extreme volatility and an eventual substantial increase, leading to a general decline in the working capital turnover ratio over the observed period.

Revenue Growth Patterns
A sustained growth trend is evident, with quarterly revenue increasing from 7,810 million US$ in March 2022 to 22,974 million US$ by June 2026. The growth acceleration becomes particularly pronounced starting in 2024, indicating a substantial scaling of commercial operations.
Working Capital Volatility and Expansion
Working capital displayed significant instability between 2022 and 2023, including a dip into negative territory (-1,566 million US$) by December 31, 2023. However, from 2024 onward, there is a marked shift toward aggressive capital accumulation. Working capital surged from 6,591 million US$ in March 2024 to a peak of 21,930 million US$ in September 2025, suggesting a strategic increase in current assets relative to current liabilities to support higher production or distribution demands.
Working Capital Turnover Analysis
The turnover ratio has transitioned from a state of high volatility to a structural decline. In 2022 and 2023, the ratio fluctuated sharply, reaching peaks above 31.00. However, as the company scaled, the ratio trended downward, falling to 2.71 by September 2025. This downward trend indicates that the growth in working capital has significantly outpaced the growth in revenue, resulting in a lower efficiency of working capital usage in generating sales.
Operational Implications
The divergence between the rising revenue and the declining turnover ratio suggests that the business is in a capital-intensive growth phase. The massive increase in working capital during 2025 and 2026 implies a heavier investment in short-term operating assets, which may be necessary to sustain the accelerated revenue growth observed in the final quarters of the analysis.

AI Ask an analyst for more



Average Inventory Processing Period

Eli Lilly & Co., average inventory processing period calculation (quarterly data)

Microsoft Excel
Jun 30, 2026 Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data
Inventory turnover 0.79 0.85 0.80 0.83 0.84 0.96 1.11 1.05 1.16 1.17 1.23 1.40 1.37 1.36 1.54 1.86 1.79 1.93
Short-term Activity Ratio (no. days)
Average inventory processing period1 463 428 454 441 435 379 329 349 316 312 298 261 267 268 237 196 204 189
Benchmarks (no. days)
Average Inventory Processing Period, Competitors2
AbbVie Inc. 102 100 99 100 107 98 90 89 75 75 73 77 85 81 75 66 73 74
Amgen Inc. 195 191 189 190 194 195 199 209 257 321 411 259 265 279 281 272 260 247
Bristol-Myers Squibb Co. 68 70 70 69 70 69 67 102 98 99 91 84 83 93 84 76 79 80
Danaher Corp. 114 94 90 99 101 96 88 101 102 98 96 104 102 104 91 96 98 94
Gilead Sciences Inc. 115 114 104 105 108 103 100 101 110 102 100 105 106 102 97 78 81 81
Johnson & Johnson 176 172 171 176 168 163 165 169 166 158 154 149 164 155 147 136 136 132
Merck & Co. Inc. 126 138 148 160 162 150 147 149 153 151 144 139 137 134 124 118 119 133
Pfizer Inc. 212 232 242 251 239 229 222 219 178 170 149 138 158 119 95 101 100 99
Regeneron Pharmaceuticals Inc. 479 491 556 571 570 582 572 573 562 553 519 508 532 549 562 440 379 287
Thermo Fisher Scientific Inc. 75 75 75 82 80 76 72 79 76 74 72 76 79 79 79 85 91 94
Vertex Pharmaceuticals Inc. 365 384 373 369 345 320 287 267 238 222 214 213 192 177 156 136 135 129

Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q2 2026 Calculation
Average inventory processing period = 365 ÷ Inventory turnover
= 365 ÷ 0.79 = 463

2 Click competitor name to see calculations.


A consistent decline in inventory management efficiency is evident over the observed period from March 31, 2022, to June 30, 2026. There is a strong inverse correlation between the inventory turnover ratio and the average inventory processing period, with the former decreasing steadily while the latter increases significantly.

Inventory Turnover Trends
The inventory turnover ratio exhibits a persistent downward trajectory. Starting at 1.93 in March 2022, the ratio decreased to 1.54 by the end of 2022 and further declined to 1.23 by December 31, 2023. This trend accelerated in subsequent years, falling below the 1.0 threshold in early 2025 and reaching a period low of 0.79 by June 30, 2026. This indicates a slowing rate of inventory replacement.
Average Inventory Processing Period Expansion
The average inventory processing period has expanded substantially, reflecting a longer duration for inventory to be converted into sales. The period began at 189 days in March 2022 and rose to 237 days by December 31, 2022. A notable escalation occurred throughout 2023 and 2024, with the period crossing the 300-day threshold in March 2024 and peaking at 463 days by June 30, 2026.
Temporal Analysis of Efficiency Loss
The data reveals three distinct phases of deceleration. Between March 2022 and December 2022, the processing period grew by approximately 25%. From January 2023 to December 2024, the period experienced a steady climb, moving from 268 days to 329 days. The most aggressive increase occurred during 2025, where the processing period jumped from 379 days in March to 454 days in December, suggesting a significant shift in operational dynamics or inventory accumulation during this window.

Overall, the operational data indicates a systemic increase in the time required to process inventory. The transition from an average processing period of under 200 days to over 460 days suggests a marked decrease in short-term operating activity efficiency.

AI Ask an analyst for more



Average Receivable Collection Period

Eli Lilly & Co., average receivable collection period calculation (quarterly data)

Microsoft Excel
Jun 30, 2026 Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data
Receivables turnover 3.97 3.92 3.67 3.69 3.76 4.07 4.09 3.97 3.53 4.56 3.75 3.93 3.93 3.68 4.14 4.35 4.57 4.64
Short-term Activity Ratio (no. days)
Average receivable collection period1 92 93 99 99 97 90 89 92 103 80 97 93 93 99 88 84 80 79
Benchmarks (no. days)
Average Receivable Collection Period, Competitors2
AbbVie Inc. 78 73 75 78 79 79 71 75 78 80 75 76 75 74 71 68 72 69
Amgen Inc. 103 94 99 90 95 91 77 86 86 88 99 88 84 84 82 79 79 76
Danaher Corp. 58 56 58 56 54 54 54 54 51 52 60 59 55 53 57 51 54 53
Gilead Sciences Inc. 62 59 62 65 61 56 56 59 62 62 63 64 57 57 65 59 55 51
Johnson & Johnson 71 67 67 70 72 65 61 67 67 64 64 62 68 65 62 60 62 60
Merck & Co. Inc. 69 68 66 69 68 62 58 66 68 68 63 64 69 66 58 59 62 66
Pfizer Inc. 72 73 69 83 69 69 66 87 74 72 69 58 48 48 40 59 55 52
Regeneron Pharmaceuticals Inc. 154 140 146 146 144 144 160 161 155 146 158 156 148 151 160 148 132 107
Thermo Fisher Scientific Inc. 74 74 73 74 73 72 70 71 68 68 70 70 67 66 66 63 66 70
Vertex Pharmaceuticals Inc. 62 60 62 61 61 59 53 60 58 64 58 58 60 61 59 58 58 59

Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q2 2026 Calculation
Average receivable collection period = 365 ÷ Receivables turnover
= 365 ÷ 3.97 = 92

2 Click competitor name to see calculations.


An overall expansion of the receivable collection cycle is observed from March 2022 through June 2026. The data indicates a transition from a more efficient collection process in early 2022 toward a lengthened cycle characterized by periodic volatility and a higher average number of days required to convert receivables into cash.

Average Receivable Collection Period Trends
A progressive increase in the collection period is evident throughout 2022, rising from 79 days in March to 88 days by December. This upward trend continued into early 2023, reaching 99 days. A notable spike occurred in June 2024, where the collection period peaked at 103 days, the highest value in the sequence. Following this peak, the duration fluctuated but remained generally elevated, stabilizing between 92 and 99 days throughout 2025 and the first half of 2026.
Receivables Turnover Dynamics
The receivables turnover ratio exhibits a consistent inverse correlation with the collection period, reflecting a decline in relative efficiency over the analyzed timeframe. The ratio began at a peak of 4.64 in March 2022 and trended downward, hitting a minimum of 3.53 in June 2024. Recent data from 2025 and 2026 show a partial recovery and stabilization of the turnover ratio between 3.67 and 3.97, although these levels remain below the efficiency benchmarks established in early 2022.

AI Ask an analyst for more



Operating Cycle

Eli Lilly & Co., operating cycle calculation (quarterly data)

No. days

Microsoft Excel
Jun 30, 2026 Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data
Average inventory processing period 463 428 454 441 435 379 329 349 316 312 298 261 267 268 237 196 204 189
Average receivable collection period 92 93 99 99 97 90 89 92 103 80 97 93 93 99 88 84 80 79
Short-term Activity Ratio
Operating cycle1 555 521 553 540 532 469 418 441 419 392 395 354 360 367 325 280 284 268
Benchmarks
Operating Cycle, Competitors2
AbbVie Inc. 180 173 174 178 186 177 161 164 153 155 148 153 160 155 146 134 145 143
Amgen Inc. 298 285 288 280 289 286 276 295 343 409 510 347 349 363 363 351 339 323
Danaher Corp. 172 150 148 155 155 150 142 155 153 150 156 163 157 157 148 147 152 147
Gilead Sciences Inc. 177 173 166 170 169 159 156 160 172 164 163 169 163 159 162 137 136 132
Johnson & Johnson 247 239 238 246 240 228 226 236 233 222 218 211 232 220 209 196 198 192
Merck & Co. Inc. 195 206 214 229 230 212 205 215 221 219 207 203 206 200 182 177 181 199
Pfizer Inc. 284 305 311 334 308 298 288 306 252 242 218 196 206 167 135 160 155 151
Regeneron Pharmaceuticals Inc. 633 631 702 717 714 726 732 734 717 699 677 664 680 700 722 588 511 394
Thermo Fisher Scientific Inc. 149 149 148 156 153 148 142 150 144 142 142 146 146 145 145 148 157 164
Vertex Pharmaceuticals Inc. 427 444 435 430 406 379 340 327 296 286 272 271 252 238 215 194 193 188

Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q2 2026 Calculation
Operating cycle = Average inventory processing period + Average receivable collection period
= 463 + 92 = 555

2 Click competitor name to see calculations.


The analyzed period reflects a significant extension of the overall operating cycle, characterized by a substantial increase in the time required to convert current assets into cash. This expansion is primarily driven by a sharp rise in inventory holding times, while the collection of receivables has remained relatively stable in comparison.

Average Inventory Processing Period
A consistent and aggressive upward trend is observed in the inventory processing period, which rose from 189 days in March 2022 to 463 days by June 2026. The most pronounced acceleration occurred between December 2023 and June 2025, where the period expanded from 298 days to 435 days. This indicates a significant slowdown in inventory turnover, suggesting that goods are remaining in stock for more than double the duration seen at the start of the period.
Average Receivable Collection Period
The collection period exhibits moderate volatility but lacks a strong linear trend compared to inventory. Starting at 79 days in March 2022, the period fluctuated between a low of 79 days and a peak of 103 days in June 2024. By June 2026, the period settled at 92 days. While there is a slight overall increase, the receivable collection process has remained comparatively efficient and is not the primary driver of the extended operating cycle.
Operating Cycle
The total operating cycle has more than doubled, increasing from 268 days in March 2022 to 555 days by June 2026. The correlation between the operating cycle and the inventory processing period is nearly absolute, confirming that the lengthening of the cash-to-cash cycle is almost entirely attributable to inventory management or production lead times. This trend represents a significant increase in the company's working capital requirements over the observed timeframe.

AI Ask an analyst for more



Average Payables Payment Period

Eli Lilly & Co., average payables payment period calculation (quarterly data)

Microsoft Excel
Jun 30, 2026 Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data
Payables turnover 2.16 2.47 2.05 2.37 2.27 2.61 2.61 2.70 2.56 2.88 2.73 2.81 2.65 3.07 3.43 4.24 4.21 5.24
Short-term Activity Ratio (no. days)
Average payables payment period1 169 148 178 154 161 140 140 135 142 127 134 130 138 119 106 86 87 70
Benchmarks (no. days)
Average Payables Payment Period, Competitors2
Amgen Inc. 90 91 72 85 89 70 54 61 73 60 69 70 64 73 90 69 72 78
Bristol-Myers Squibb Co. 103 108 94 107 140 104 94 106 120 117 111 97 108 114 109 96 107 112
Danaher Corp. 64 64 67 63 65 66 66 60 63 62 65 65 63 64 67 65 73 72
Gilead Sciences Inc. 40 38 42 48 34 43 49 49 29 34 31 37 40 41 58 33 31 32
Johnson & Johnson 107 123 145 119 119 123 137 120 121 113 132 111 133 120 137 118 116 112
Merck & Co. Inc. 78 82 98 103 95 92 98 86 83 81 89 80 80 84 89 71 75 86
Pfizer Inc. 98 98 119 110 106 110 115 99 79 87 98 72 93 76 72 66 59 55
Regeneron Pharmaceuticals Inc. 180 163 163 158 129 129 146 94 110 137 122 106 116 136 138 98 91 68
Thermo Fisher Scientific Inc. 43 46 50 44 43 44 45 38 37 37 41 35 34 39 48 37 41 46
Vertex Pharmaceuticals Inc. 89 106 102 95 102 105 98 98 85 96 106 117 115 107 103 44 73 66

Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q2 2026 Calculation
Average payables payment period = 365 ÷ Payables turnover
= 365 ÷ 2.16 = 169

2 Click competitor name to see calculations.


The analysis of short-term operating activity reveals a consistent expansion in the timeframe required to settle accounts payable from March 2022 through June 2026. A clear inverse correlation exists between the payables turnover ratio and the average payment period, indicating a sustained trend toward extending supplier credit terms.

Payables Turnover Trend
A steady decline in the payables turnover ratio is observed, falling from 5.24 in March 2022 to 2.16 by June 2026. This downward trajectory indicates that the company is cycling through its accounts payable less frequently, which effectively slows the outflow of cash to suppliers.
Average Payables Payment Period Expansion
The average period for settling obligations demonstrates a significant upward trend, increasing from 70 days in March 2022 to 169 days by June 2026. A period of rapid acceleration is noted between March 2022 and June 2023, where the duration increased from 70 to 138 days. The payment period reached its peak of 178 days in December 2025, representing more than a twofold increase from the start of the analyzed period.
Analysis of Periodic Fluctuations
Despite the overall upward trajectory, intermittent contractions in the payment period are present. Notable dips occurred in March 2024 (127 days) and March 2026 (148 days). These variations suggest occasional accelerations in payment settlements, although they are insufficient to offset the broader trend of extending payment cycles.
Operational Implications
The progression from a 70-day to a 169-day payment cycle suggests an increase in the company's ability to leverage supplier financing. This shift results in higher current liabilities but enhances short-term liquidity by retaining cash within the organization for longer durations.

AI Ask an analyst for more



Cash Conversion Cycle

Eli Lilly & Co., cash conversion cycle calculation (quarterly data)

No. days

Microsoft Excel
Jun 30, 2026 Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data
Average inventory processing period 463 428 454 441 435 379 329 349 316 312 298 261 267 268 237 196 204 189
Average receivable collection period 92 93 99 99 97 90 89 92 103 80 97 93 93 99 88 84 80 79
Average payables payment period 169 148 178 154 161 140 140 135 142 127 134 130 138 119 106 86 87 70
Short-term Activity Ratio
Cash conversion cycle1 386 373 375 386 371 329 278 306 277 265 261 224 222 248 219 194 197 198
Benchmarks
Cash Conversion Cycle, Competitors2
Amgen Inc. 208 194 216 195 200 216 222 234 270 349 441 277 285 290 273 282 267 245
Danaher Corp. 108 86 81 92 90 84 76 95 90 88 91 98 94 93 81 82 79 75
Gilead Sciences Inc. 137 135 124 122 135 116 107 111 143 130 132 132 123 118 104 104 105 100
Johnson & Johnson 140 116 93 127 121 105 89 116 112 109 86 100 99 100 72 78 82 80
Merck & Co. Inc. 117 124 116 126 135 120 107 129 138 138 118 123 126 116 93 106 106 113
Pfizer Inc. 186 207 192 224 202 188 173 207 173 155 120 124 113 91 63 94 96 96
Regeneron Pharmaceuticals Inc. 453 468 539 559 585 597 586 640 607 562 555 558 564 564 584 490 420 326
Thermo Fisher Scientific Inc. 106 103 98 112 110 104 97 112 107 105 101 111 112 106 97 111 116 118
Vertex Pharmaceuticals Inc. 338 338 333 335 304 274 242 229 211 190 166 154 137 131 112 150 120 122

Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q2 2026 Calculation
Cash conversion cycle = Average inventory processing period + Average receivable collection period – Average payables payment period
= 463 + 92169 = 386

2 Click competitor name to see calculations.


The cash conversion cycle has demonstrated a significant upward trajectory over the analyzed period, increasing from 198 days in March 2022 to 386 days by June 2026. This extension indicates a slower turnaround of working capital, primarily driven by a substantial increase in the time required to process inventory, which has been partially mitigated by an extension in the payment of accounts payable.

Average Inventory Processing Period
A consistent and pronounced increase is observed in the inventory processing period, which rose from 189 days in March 2022 to 463 days in June 2026. The growth was particularly accelerated between March 2024 and June 2026, where the period climbed from 312 days to 463 days. This trend suggests a significant accumulation of inventory or a slowing of inventory turnover rates.
Average Receivable Collection Period
The receivable collection period remained relatively stable compared to other operating metrics. While it fluctuated between a low of 79 days in March 2022 and a peak of 103 days in June 2024, it concluded the period at 92 days in June 2026. This stability indicates that credit collection efficiency has remained largely consistent despite the growth in other cycle components.
Average Payables Payment Period
There is a clear upward trend in the payables payment period, increasing from 70 days in March 2022 to 169 days in June 2026. This suggests a strategic shift toward extending payment terms with suppliers, which serves as a financing mechanism to offset the liquidity pressures caused by the lengthening inventory processing period.
Cash Conversion Cycle Dynamics
The overall expansion of the cash conversion cycle is the result of the inventory processing period increasing at a faster rate than the payables payment period. While the increase in payables provided a buffer, it was insufficient to neutralize the impact of the inventory build-up, leading to a net increase of 188 days in the total cycle over the period analyzed.

AI Ask an analyst for more